Lancet 376(9747):11471154 Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C et al (2024) Long-term outcomes of a randomized, open-label, phase II study comparing Cabazitaxel versus Paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
There were no reported side effects, and the treatment was well tolerated.30 Moreover, BPC-157 is very safe
The glutathione antioxidant for skin also accelerates cellular turnover, helping damaged, hyperpigmented cells shed more efficiently whilst protecting newly formed cells from oxidative damage
Compounding pharmacies must maintain state licensing and FDA registration
However, it was lower than previously reported: 32/98 (32.7%) in France 11 , and 7/14 (50.0%) in the USA 34
In studies, tirzepatide users lost up to 22.5% of their body weight, setting a new benchmark among weight loss medications